Advanced glycated albumin isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene expression impairing ABCA-1-mediated reverse cholesterol transport

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 1, 2013, Pages 66-76

  Machado Lima, Adriana ^a   Iborra, Rodrigo T ^a   Pinto, Raphael S ^a   Sartori, Camila H ^a   Oliveira, Erika R ^a   Nakandakare, Edna R ^a   Stefano, José T ^a   Giannella Neto, Daniel ^a   Corrêa Giannella, Maria Lucia C ^a   Passarelli, Marisa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ABCA 1; Advanced glycation end product; Albumin; Diabetes; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; ACYL COENZYME A DESATURASE; APOLIPOPROTEIN; CARBON 14; CHOLESTEROL; GLYCOSYLATED ALBUMIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; JANUS KINASE 2;

ADULT; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETES CONTROL; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GLYCATION; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; LIPID STORAGE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; FEMALE; GENE EXPRESSION; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MALE; SERUM ALBUMIN;

EID: 84872250460     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2362     Document Type: Article

References (39)

1. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, Nathan DM, Cleary PA, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643-2653.
2. Kumeda Y, Inaba M, Shoji S, et al. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf) 2008; 69(4): 556-561.
3. Peppa M, Raptis SA. Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev 2008; 4(2): 92-100.
4. Masumi AI, Otokozawa S, Schaefer EJ, et al. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clin Chim Acta 2009; 406(1-2): 71-74.
5. Pu LJ, Lu L, Shen WF, et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007; 71(7): 1067-1073.
6. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261(11): 4889-4894.
7. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251(2): 87-101.
8. Baidoshvili A, Niessen HW, Stooker W, et al. N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis 2004; 174(2): 287-292.
9. Yeh CH, Sturgis L, Haidacher J, et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001; 50(6): 1495-1504.
10. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114(6): 597-605.
11. Ywashima Y, Eto M, Hata A, et al. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 2000; 277: 368-380.
12. Horiuchi S, Unno Y, Usui H, et al. Pathological roles of advanced glycation end product receptors SR-A and CD36. Ann N Y Acad Sci 2005; 1043: 671-675.
13. Ohkawara E, Nohara Y, Kanno Y, et al. Fructosamine assay using albumin extracted from serum. Biol Pharm Bull 2002; 25(9): 1121-1124.
14. Basu SK, Goldstein JL, Anderson GW, Brown MS. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci USA 1976; 73(9): 3178-3182.
15. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
16. Machado AP, Pinto RS, Moyses ZP, Nakandakare ER, Quintao EC, Passarelli M. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int J Biochem Cell Biol 2006; 38(3): 392-403.
17. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond) 2005; 109(4): 365-379.
18. Kubista M, Andrade JM, Bengtsson M, et al. The real-time polymerase chain reaction. Mol Aspects Med 2006; 27(2-3): 95-125.
19. Terpstra AH, Nicolosi RJ, Herbert PN. In vitro incorporation of radiolabeled cholesteryl esters into high and low density lipoproteins. J Lipid Res 1989; 30(11): 1663-1671.
20. Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. Coron Artery Dis 2009; 20(4): 267-273.
21. Baumann M, Richart T, Sollinger D, et al. Association between carotid diameter and the advanced glycation endproduct N-epsilon-carboxymethyllysine (CML). Cardiovasc Diabetol 2009; 8: 45.
22. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007; 117(8): 2216-2224.
23. Tarr PT, Tarling EJ, Bojanic DD, Edwards PA, Baldán A. Emerging new paradigms for ABCG transporters. Biochim Biophys Acta 2009; 1791(7): 584-593.
24. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994; 107: 85-98.
25. Passarelli M, Tang C, Mcdonald TO, et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 2005; 54(7): 2198-2205.
26. de Souza Pinto R, Castilho G, Paim BA, et al. Inhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albumin. Lipids 2012; 47(5): 443-450.
27. Castilho G, Okuda LS, Pinto RS, et al. ER stress is associated with reduced ABCA-1 protein levels in macrophages treated with advanced glycated albumin - reversal by a chemical chaperone. Int J Biochem Cell Biol 2012; 44(7): 1078-1086.
28. Iborra RT, Machado-Lima A, Castilho G, et al. Advanced glycation in macrophages induces intracellular accumulation of 7-ketocholesterol and total sterols by decreasing the expression of ABCA-1 and ABCG-1. Lipids Health Dis 2011; 29(10): 172.
29. Sun Y, Hao M, Luo Y, et al. Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure. J Biol Chem 2003; 278(8): 5813-5820.
30. Wang Y, Kurdi-Haidar B, Oram JF. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res 2004; 45(5): 972-980.
31. Tang C, Vaughan AM, Oram JF. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem 2004; 279(9): 7622-7628.
32. Passarelli M, Catanozi S, Nakandakare ER, et al. Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia 1997; 40(9): 1085-1093.
33. Ohgami N, Nagai R, Miyazaki A, et al. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 2001; 276: 13348-13355.
34. Sayre LM, Sha W, Xu G, et al. Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal. Chem Res Toxicol 1996; 9(7): 1194-1201.
35. Xu G, Liu Y, Kansal MM, Sayre LM. Rapid cross-linking of proteins by 4-ketoaldehydes and 4-hydroxy-2-alkenals does not arise from the lysine-derived monoalkylpyrroles. Chem Res Toxicol 1999; 12(9): 855-861.
36. Morris MA, Preddy L. Glycosylation accelerates albumin degradation in normal and diabetic dogs. Biochem Med Metab Biol 1986; 35(3): 267-270.
37. Layton GJ, Jerums G. Effect of glycation of albumin on its renal clearance in normal and diabetic rats. Kidney Int 1988; 33(3): 673-676.
38. 14C-glycated albumin from serum of rabbit. Scand J Clin Lab Invest 1990; 50(7): 763-768.
39. Nerlich AG, Schleicher ED. N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis 1999; 144(1): 41-47.